[go: up one dir, main page]

PL2888280T3 - Ludzkie przeciwciała przeciwko GFR 3 i sposoby ich użycia - Google Patents

Ludzkie przeciwciała przeciwko GFR 3 i sposoby ich użycia

Info

Publication number
PL2888280T3
PL2888280T3 PL13753402T PL13753402T PL2888280T3 PL 2888280 T3 PL2888280 T3 PL 2888280T3 PL 13753402 T PL13753402 T PL 13753402T PL 13753402 T PL13753402 T PL 13753402T PL 2888280 T3 PL2888280 T3 PL 2888280T3
Authority
PL
Poland
Prior art keywords
gfr
methods
human antibodies
antibodies
human
Prior art date
Application number
PL13753402T
Other languages
English (en)
Inventor
Susan D. Croll
Lynn Macdonald
Andrew J. Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49036666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2888280(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PL2888280T3 publication Critical patent/PL2888280T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
PL13753402T 2012-08-22 2013-08-21 Ludzkie przeciwciała przeciwko GFR 3 i sposoby ich użycia PL2888280T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261692029P 2012-08-22 2012-08-22
PCT/US2013/055921 WO2014031712A1 (en) 2012-08-22 2013-08-21 HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
EP13753402.0A EP2888280B1 (en) 2012-08-22 2013-08-21 Human antibodies to gfr 3 and methods of use thereof

Publications (1)

Publication Number Publication Date
PL2888280T3 true PL2888280T3 (pl) 2019-04-30

Family

ID=49036666

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13753402T PL2888280T3 (pl) 2012-08-22 2013-08-21 Ludzkie przeciwciała przeciwko GFR 3 i sposoby ich użycia

Country Status (34)

Country Link
US (5) US8968736B2 (pl)
EP (2) EP2888280B1 (pl)
JP (3) JP6392755B2 (pl)
KR (1) KR102158569B1 (pl)
CN (2) CN104768974B (pl)
AR (1) AR092188A1 (pl)
AU (1) AU2013305863B2 (pl)
CA (1) CA2879724C (pl)
CL (1) CL2015000420A1 (pl)
CY (1) CY1121097T1 (pl)
DK (1) DK2888280T3 (pl)
EA (2) EA034683B1 (pl)
ES (1) ES2700160T3 (pl)
HR (1) HRP20190109T1 (pl)
HU (1) HUE042943T2 (pl)
IL (1) IL236738B (pl)
JO (1) JO3462B1 (pl)
LT (1) LT2888280T (pl)
MA (1) MA37945B1 (pl)
MX (1) MX363541B (pl)
MY (2) MY184241A (pl)
NZ (1) NZ704007A (pl)
PH (1) PH12015500114A1 (pl)
PL (1) PL2888280T3 (pl)
PT (1) PT2888280T (pl)
RS (1) RS58311B1 (pl)
SG (2) SG10201701376UA (pl)
SI (1) SI2888280T1 (pl)
SM (1) SMT201900022T1 (pl)
TR (1) TR201816597T4 (pl)
TW (2) TWI613218B (pl)
UY (1) UY34988A (pl)
WO (1) WO2014031712A1 (pl)
ZA (1) ZA201500336B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
WO2016025884A1 (en) * 2014-08-14 2016-02-18 The Trustees Of The University Of Pennsylvania Glycosyl-phosphatidylinositol (gpi)-linked gdnf family alpha-receptor 4 (gfralpha4)-specific antibody and uses thereof
US10729771B2 (en) 2016-02-10 2020-08-04 Rutgers, The State University Of New Jersey Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infections
US20170281756A1 (en) * 2016-02-25 2017-10-05 University Of Southern California Compositions and methods to selectively block pain induced by cold
CN108697795A (zh) * 2016-02-29 2018-10-23 伊莱利利公司 Gfral受体疗法
JP7021099B2 (ja) 2016-03-31 2022-02-18 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 結合タンパク質及びその使用方法
JP7000349B2 (ja) 2016-05-13 2022-02-04 インスティテュート デ メディシナ モレキュラー ジョアオ ロボ アントゥネス Ｉｌｃ３細胞に関連する疾患を処置する方法
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
CN107827983B (zh) * 2017-11-06 2020-09-25 中国药科大学 一种靶向artn的单链抗体、制备方法及应用
CN112165957A (zh) * 2018-03-26 2021-01-01 上海易乐生物技术有限公司 proBDNF调节剂在B细胞相关疾病中的用途
WO2019210144A1 (en) * 2018-04-27 2019-10-31 Vanderbilt University Broadly neutralizing antibodies against hepatitis c virus
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
US11407828B2 (en) 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
MA55615A (fr) * 2019-04-10 2022-02-16 Regeneron Pharma Anticorps humains qui se lient au ret et leurs procédés d'utilisation
US11802159B2 (en) 2019-09-30 2023-10-31 The Trustees Of The University Of Pennsylvania Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs)
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN117177993B (zh) 2021-04-20 2025-06-20 瑞泽恩制药公司 针对artemin的人抗体及其使用方法
JP2024522938A (ja) 2021-06-03 2024-06-21 フンダサン デー．アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド 脳－脂肪回路を介してｉｌｃ２および肥満度を制御する神経－間葉単位
EP4472738A1 (en) * 2022-01-31 2024-12-11 Glaxosmithkline Intellectual Property (N0.3) Limited Prevention and treatment of headaches
US20250241951A1 (en) * 2023-01-18 2025-07-31 Texas Tech University System Gfra2 antibodies and their use in cancer treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138251B1 (en) 1996-04-22 2006-11-21 Amgen Inc. Polynucleotides encoding a neurotrophic factor receptor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
CA2323072C (en) * 1998-03-23 2011-05-24 Genentech, Inc. Gfr.alpha.3 and its uses
US7026138B1 (en) 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
HK1045528B (zh) * 1998-07-14 2006-10-27 詹森药业有限公司 神经营养生长因子
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
EP1896047A4 (en) * 2005-06-17 2009-07-22 Biogen Idec Inc ANTI-GFRALPHA3 ANTIBODIES
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
BRPI0811857A2 (pt) * 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
JP2010534469A (ja) 2007-07-25 2010-11-11 アストラゼネカ アクチボラグ Ｋｄｒ指向性標的化結合物質およびその使用
WO2009020964A2 (en) 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
SMT201900372T1 (it) 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
CA2820134A1 (en) 2010-12-06 2012-06-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها

Also Published As

Publication number Publication date
JP6392755B2 (ja) 2018-09-19
LT2888280T (lt) 2018-12-10
ZA201500336B (en) 2019-12-18
HK1206037A1 (en) 2015-12-31
EA202090031A2 (ru) 2020-04-30
EP3450458B1 (en) 2021-07-14
HRP20190109T1 (hr) 2019-03-08
HUE042943T2 (hu) 2019-07-29
TW201420603A (zh) 2014-06-01
AR092188A1 (es) 2015-04-08
CA2879724A1 (en) 2014-02-27
SMT201900022T1 (it) 2019-02-28
RS58311B1 (sr) 2019-03-29
MX2015002289A (es) 2016-06-07
EA201590402A1 (ru) 2015-09-30
ES2700160T3 (es) 2019-02-14
CN104768974A (zh) 2015-07-08
US9522185B2 (en) 2016-12-20
TW201819415A (zh) 2018-06-01
PH12015500114B1 (en) 2015-03-16
SG11201500501VA (en) 2015-02-27
CA2879724C (en) 2023-03-14
UY34988A (es) 2014-03-31
CN109096398A (zh) 2018-12-28
TWI613218B (zh) 2018-02-01
EP3450458A1 (en) 2019-03-06
US20140056903A1 (en) 2014-02-27
BR112015003110A2 (pt) 2018-08-28
MA37945B1 (fr) 2017-05-31
US20200040087A1 (en) 2020-02-06
IL236738B (en) 2022-04-01
AU2013305863A1 (en) 2015-02-05
DK2888280T3 (en) 2018-12-10
JO3462B1 (ar) 2020-07-05
US20170096488A1 (en) 2017-04-06
CN104768974B (zh) 2018-08-14
EA034683B1 (ru) 2020-03-05
SG10201701376UA (en) 2017-03-30
AU2013305863B2 (en) 2018-06-07
MY184241A (en) 2021-03-29
US8968736B2 (en) 2015-03-03
SI2888280T1 (sl) 2019-03-29
CY1121097T1 (el) 2019-12-11
EP2888280A1 (en) 2015-07-01
IL236738A0 (en) 2015-02-26
CL2015000420A1 (es) 2015-05-22
TR201816597T4 (tr) 2018-11-21
JP6718482B2 (ja) 2020-07-08
KR20150041664A (ko) 2015-04-16
MX363541B (es) 2019-03-27
US10077311B2 (en) 2018-09-18
NZ704007A (en) 2018-08-31
EP2888280B1 (en) 2018-10-17
JP2018143252A (ja) 2018-09-20
KR102158569B1 (ko) 2020-09-22
TWI631139B (zh) 2018-08-01
PT2888280T (pt) 2019-01-21
WO2014031712A1 (en) 2014-02-27
JP2015532647A (ja) 2015-11-12
US20150110801A1 (en) 2015-04-23
US10947312B2 (en) 2021-03-16
US20180340029A1 (en) 2018-11-29
MY167920A (en) 2018-09-27
MA37945A1 (fr) 2016-02-29
PH12015500114A1 (en) 2015-03-16
EA202090031A3 (ru) 2020-07-31
JP2020031662A (ja) 2020-03-05

Similar Documents

Publication Publication Date Title
PT2888280T (pt) Anticorpos humanos para gfrα3 humano e métodos de uso dos mesmos
IL235121A0 (en) Human antibodies to fel d1 and methods of using them
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
SI2806892T1 (sl) Kombinirana terapevtska uporaba protiteles in endoglikozidaz
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
PL2922557T3 (pl) Suplementy ziołowe i sposoby ich zastosowania
PL2790666T3 (pl) Ekstrakty z maesa japonica i sposoby zastosowania
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
IL229748A0 (en) Compounds that bind to human β1-adrenoceptor (ß1-ar) and their use in the measurement of ar-a1 autoantibodies
EP2825199A4 (en) ANTIBODIES AGAINST HUMAN AUTOTAXIN AND METHODS OF USE
GB201223374D0 (en) Personal care composition and methods of making the same
SI2937095T1 (sl) Izvleček otrobov semena lacryma-jobi coix in njegova uporaba